Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Jacek Szepietowski
Wroclaw Medical University, Wroclaw, Poland

Kim Papp
Probity Medical Research, Waterloo, ON, Canada

Eric Simpson
Oregon Health & Science University, Portland, OR, USA

Jonathan Silverberg
George Washington University School of Medicine

Brian Kim
Washington University School of Medicine, St. Louis, MO, USA

Shawn Kwatra
Johns Hopkins University School of Medicine, Baltimore, MD, USA

Michael Kuligowski
Incyte Corporation, Wilmington, DE, USA

May Venturanza
Incyte Corporation, Wilmington, DE, USA

Kang Sun
Incyte Corporation, Wilmington, DE, USA

Leon Kircik
Mount Sinai

Keywords

itch, atopic dermatitis, ruxolitinib cream

Abstract

N/A


 


 


 


 


 

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(3):340-347.

3. Chrostowska-Plak D, et al. Acta Derm Venereol. 2009;89(4):379-383.

4. Wei W, et al. J Dermatol. 2018;45(2):150-157.

5. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

6. Oetjen LK, et al. Cell. 2017;171(1):217-228.

7. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

8. Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.64

Article Details

How to Cite
Blauvelt, A. ., Szepietowski, J., Papp, K. ., Simpson, E., Silverberg, J., Kim, B. ., Kwatra, S., Kuligowski, M. ., Venturanza, M., Sun, K., & Kircik, L. (2021). Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream. SKIN The Journal of Cutaneous Medicine, 5(6), s64. https://doi.org/10.25251/skin.5.supp.64
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>